SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Ropivacaine Kabi 5 mg/ml solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml solution for injection contains 5 mg ropivacaine hydrochloride. Each 10 ml ampoule contains 50 mg ropivacaine hydrochloride.

Excipients with known effect:
Each 10 ml ampoule contains 1.38 mmol (or 31.7 mg) of sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection.

Clear, colourless solution with a pH of 4.0 to 6.0 and an osmolality between 270 and 330 mOsmol/kg.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Ropivacaine Kabi 5 mg/ml is indicated for intrathecal administration for surgical anaesthesia.

4.2 Posology and method of administration

Ropivacaine Kabi should only be used by, or under the supervision of, clinicians experienced in regional anaesthesia.

Posology

Adults and adolescents (>12 years of age)

The following table is a guide to dosage for intrathecal block in adults. The smallest dose required to produce an effective block should be used. The clinician's experience and knowledge of the patient's physical status are of importance when deciding the dose.

<table>
<thead>
<tr>
<th></th>
<th>Concentration mg/ml</th>
<th>Volume ml</th>
<th>Dose mg</th>
<th>Onset minutes</th>
<th>Duration hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>SURGICAL ANAESTHESIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrathecal Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>5.0</td>
<td>3-5</td>
<td>15-25</td>
<td>1-5</td>
<td>2-6</td>
</tr>
</tbody>
</table>
The doses in the table are those considered to be necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration occur. The figures in the column 'Dose' reflect the expected average dose range needed. Standard textbooks should be consulted for both factors affecting specific block techniques and individual patient requirements.

Renal impairment
Normally there is no need to modify the dose in patients with impaired renal function when used for single dose or short-term treatment (see section 4.4. and 5.2).

Hepatic impairment
Ropivacaine hydrochloride is metabolised in the liver and should therefore be used with caution in patients with severe liver disease. Repeated doses may need to be reduced due to delayed elimination (see section 4.4. and 5.2).

Paediatric patients (<12 years)
There is no experience with intrathecal administration, neither in infants and toddlers nor in children (see section 4.4 and 5.2).

Method of administration
Intrathecal administration by injection.

Careful aspiration before and during injection is recommended to prevent intravascular injection. An inadvertent intravascular injection may be recognised by a temporary increase in heart rate.

Aspiration should be performed prior to and during administration of the main dose, which should be injected slowly, at a rate of 25-50 mg/min, while closely observing the patient’s vital functions and maintaining verbal contact. If toxic symptoms occur, the injection should be stopped immediately.

The intrathecal injection should be made after the subarachnoid space has been identified and clear cerebrospinal fluid (CFS) is seen to escape from the spinal needle, or is detected by aspiration.

4.3 Contraindications

- Hypersensitivity to the active substance, to other local anaesthetics of the amide type, or to any of the excipients listed in section 6.1
- General contraindications related to regional anaesthesia, regardless of the local anaesthetic used, should be taken into account
- Intravenous regional anaesthesia
- Obstetric paracervical anaesthesia
- Major nerve blocks are contraindicated in hypovolaemic patients

4.4 Special warnings and precautions for use

Regional anaesthetic procedures should always be performed in a properly equipped and staffed area. Equipment and medicinal products necessary for monitoring and emergency resuscitation should be immediately available.

Patients receiving major blocks should be in an optimal condition and have an intravenous line inserted before the blocking procedure.

The clinician responsible should take the necessary precautions to avoid intravascular injection (see section 4.2) and be appropriately trained and familiar with diagnosis and treatment of undesirable
effects, systemic toxicity and other complications (see section 4.8 and 4.9). After intrathecal administration, systemic toxicity is not expected to occur, due to the low dose administered. An excessive dose administered into the subarachnoid space may give rise to a total spinal block (see section 4.9).

*Hypersensitivity*
A possible cross – hypersensitivity with other amide – type local anaesthetics should be taken into account (see section 4.3).

*Hypovolaemia*
Patients with hypovolaemia due to any cause can develop sudden and severe hypotension during intrathecal anaesthesia, regardless of the local anaesthetic used (see section 4.3).

*Patients in poor general condition*
Patients in poor general condition due to ageing or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention, however regional anaesthesia is frequently indicated in these patients.

*Patients with renal and hepatic impairment*
Ropivacaine hydrochloride is metabolised in the liver and should therefore be used with caution in patients with severe liver disease. Repeated doses may need to be reduced due to delayed elimination.

Normally there is no need to modify the dose in patients with impaired renal function when used for single dose or short-term treatment. Acidosis and reduced plasma protein concentration, frequently seen in patients with chronic renal failure, may increase the risk of systemic toxicity.

*Acute porphyria*
Ropivacaine Kabi solution for injection is possibly porphyrinogenic and should only be prescribed to patients with acute porphyria when no safer alternative is available. Appropriate precautions should be taken in the case of vulnerable patients, according to standard text books and/or in consultation with disease area experts.

*Prolonged administration*
Prolonged administration of ropivacaine hydrochloride should be avoided in patients concomitantly treated with strong CYP1A2 inhibitors, such as fluvoxamine and enoxacin, (see section 4.5).

*Paediatric patients*
Intrathecal administration for use in infants or children has not been documented.

This medicinal product contains 0.138 mmol (or 3.17 mg) sodium per ml. To be taken into consideration by patients on a controlled sodium diet.

### 4.5 Interaction with other medicinal products and other forms of interaction

Ropivacaine hydrochloride should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics, e.g., certain antiarrhythmics, such as lidocaine and mexiletine, since the systemic toxic effects are additive. Simultaneous use of Ropivacaine Kabi with general anaesthetics or opioids may potentiate each other’s (adverse) effects. Specific interaction studies with ropivacaine hydrochloride and anti-arrhythmic drugs class III (e.g., amiodarone) have not been performed, but caution is advised (see section 4.4).

Cytochrome P450 (CYP)1A2 is involved in the formation of 3-hydroxy ropivacaine, the major metabolite.
In vivo the plasma clearance of ropivacaine hydrochloride was reduced by up to 77% during co-administration of fluvoxamine, a selective and potent CYP1A2 inhibitor. Thus, strong inhibitors of CYP1A2, such as fluvoxamine and enoxacin, given concomitantly with Ropivacaine Kabi, can interact with ropivacaine hydrochloride. Prolonged administration of ropivacaine hydrochloride should be avoided in patients concomitantly treated with strong CYP1A2 inhibitors, (see section 4.4).

In vivo the plasma clearance of ropivacaine hydrochloride was reduced by 15 % during co-administration of ketoconazole, a selective and potent inhibitor of CYP3A4. However, the inhibition of this isozyme is not likely to have clinical relevance.

In vitro, ropivacaine hydrochloride is a competitive inhibitor of CYP2D6 but does not seem to inhibit this isozyme at clinically attained plasma concentrations.

4.6 Fertility, pregnancy and lactation

Pregnancy
Apart from epidural administration for obstetrical use, there are no adequate data on the use of ropivacaine hydrochloride in human pregnancy. Experimental animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).

Lactation
There is no data available concerning the excretion of ropivacaine hydrochloride into human breast milk.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Depending on the dose, local anaesthetics may have a minor influence on mental function and coordination even in the absence of overt CNS toxicity and may temporarily impair locomotion and alertness.

4.8 Undesirable effects

The adverse reaction profile for Ropivacaine Kabi is similar to those for other long acting local anaesthetics of the amide type. Adverse reactions should be distinguished from the physiological effects of the nerve block itself e.g., hypotension and bradycardia during intrathecal anaesthesia, and events caused by needle puncture (e.g., spinal haematoma, postdural puncture headache, meningitis and epidural abscess).

The most frequently reported adverse reactions, nausea and hypotension, are very frequent during anaesthesia and surgery in general and it is not possible to distinguish those caused by the clinical situation from those caused by the medicinal product or the block.

Total spinal block may occur with all local anaesthetics if an epidural dose is inadvertently administered intrathecally, or if a too large intrathecal dose is administered. Systemic and localised adverse reactions of ropivacaine hydrochloride usually occur because of excessive dosage, rapid absorption, or inadvertent intravascular injection. However, due to the low doses used for intrathecal anaesthesia, systemic toxic reactions are not expected.

The frequency of undesirable effects listed below is defined using the following convention:

- **Very common**: $\geq 1/10$
- **Common**: $1/100$ to $<1/10$
- **Uncommon**: $1/1,000$ to $<1/100$
Rare  ≥1/10,000 to <1/1,000  
Very rare  <1/10,000  
Not known  cannot be estimated from the available data  

**Psychiatric disorders:**

Uncommon:  Anxiety  

**Nervous system disorders:**

Common:  Headache, paraesthesia, dizziness  
Uncommon:  Symptoms of CNS toxicity (convulsions, grand mal convulsions, seizures, light headedness, circumoral paraesthesia, numbness of the tongue, hyperacusis, tinnitus, visual disturbances, dysarthria, muscular twitching, tremor)*, hypoaesthesia  

**Cardiac disorders:**

Common:  Bradycardia, tachycardia  
Rare:  Cardiac arrest, cardiac arrhythmias  

**Vascular disorders:**

Very common:  Hypotension  
Common:  Hypertension  
Uncommon:  Syncope  

**Respiratory, thoracic and mediastinal disorders:**

Uncommon:  Dyspnoea  

**Gastrointestinal disorders:**

Very common:  Nausea  
Common:  Vomiting  

**Renal and urinary disorders:**

Common:  Urinary retention  

**General disorders and administration site conditions:**

Common:  Back pain, hyperthermia, rigors  
Uncommon:  Hypothermia  
Rare:  Allergic reactions (anaphylactic reactions, angioneurotic oedema and urticaria)*  

*These symptoms usually occur because of inadvertent intravascular injection, overdose or rapid absorption (see section 4.9).  
* Hypotension is less frequent in children (>1/100).  
* Vomiting is more frequent in children. (>1/10).  

**Class-related adverse reactions**  

**Neurological complications**

Neuropathy and spinal cord dysfunction (e.g., anterior spinal artery syndrome, arachnoiditis, cauda equina), which may result in rare cases of permanent sequelae, have been associated with regional anaesthesia, regardless of the local anaesthetic used.  

**Total spinal block**

Total spinal block may occur if a too large intrathecal dose is administered.
Acute systemic toxicity
Systemic toxic reactions primarily involve the central nervous system (CNS) and the cardiovascular system (CVS). Such reactions are caused by high blood concentration of a local anaesthetic, which may appear due to (accidental) intravascular injection, overdose or exceptionally rapid absorption from highly vascularised areas (see section 4.4). CNS reactions are similar for all amide local anaesthetics, while cardiac reactions are more dependent on the active substance, both quantitatively and qualitatively.

Central nervous system
Central nervous system toxicity is a graded response with symptoms and signs of escalating severity. Initially symptoms such as visual or auditory disturbances, perioral numbness, dizziness, light-headedness, tingling and paraesthesia are seen. Dysarthria, muscular rigidity and muscular twitching are more serious and may precede the onset of generalised convulsions. These signs must not be mistaken for an underlying neurological disease. Unconsciousness and tonic-clonic (grand mal) convulsions may follow, which may last from a few seconds to several minutes. Hypoxia and hypercarbia occur rapidly during convulsions due to the increased muscular activity, together with the interference with respiration. In severe cases even apnoea may occur. The respiratory and metabolic acidosis increases and extends the toxic effects of local anaesthetics.

Recovery follows the redistribution of the active substance from the central nervous system and subsequent metabolism and excretion. Recovery may be rapid unless large amounts of the medicinal product have been injected.

Cardiovascular toxicity
Cardiovascular toxicity indicates a more severe situation. Hypotension, bradycardia, arrhythmia and even cardiac arrest may occur as a result of high systemic concentrations of local anaesthetics. In volunteers the intravenous infusion of ropivacaine hydrochloride resulted in signs of depression of conductivity and contractility.

Cardiovascular toxic effects are generally preceded by signs of toxicity in the central nervous system, unless the patient is receiving a general anaesthetic or is heavily sedated with medicinal products such as benzodiazepines or barbiturates.

Paediatric patients
In paediatric patients, early signs of local anaesthetic toxicity may be difficult to detect since they may not be able to verbally express them, or if they are under general anaesthesia (see section 4.4).

Ropivacaine Kabi is not intended for use in children <12 years of age.

4.9 Overdose

Symptoms of overdose
Accidental intravascular injections of local anaesthetics may cause immediate (within seconds to a few minutes) systemic toxic reactions. In the event of overdose, peak plasma concentrations may not be reached for one to two hours, depending on the site of the injection, and signs of toxicity may thus be delayed (see section 4.8. “Acute systemic toxicity”, “Central nervous system” and “Cardiovascular toxicity”).
After intrathecal administration, systemic toxicity is not expected to occur, due to the low dose administered. An excessive dose administered into the subarachnoid space may give rise to a total spinal block.

**Treatment of overdose**

If signs of acute systemic toxicity block appear, injection of the local anaesthetic should be stopped immediately and CNS symptoms (convulsions, CNS depression) must promptly be treated with appropriate airway/respiratory support and the administration of anticonvulsant drugs.

If circulatory arrest should occur, immediate cardiopulmonary resuscitation should be instituted. Optimal oxygenation and ventilation and circulatory support as well as treatment of acidosis are of vital importance.

If cardiovascular depression occurs (hypotension, bradycardia), appropriate treatment with intravenous fluids, vasopressor, and/or inotropic agents should be considered. Children should be given doses commensurate with age and weight.

Should cardiac arrest occur, a successful outcome may require prolonged resuscitative efforts.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

Pharmacotherapeutic group: Anaesthetics, local, Amides, ATC code: N01BB09

Ropivacaine hydrochloride is a long-acting amide-type local anaesthetic with both anaesthetic and analgesic effects. At high doses ropivacaine hydrochloride produces surgical anaesthesia, while at lower doses it produces sensory block with limited and non-progressive motor block.

The mechanism is a reversible reduction of the membrane permeability of the nerve fibre to sodium ions. Consequently the depolarisation velocity is decreased and the excitable threshold increased, resulting in a local blockade of nerve impulses.

The most characteristic property of ropivacaine hydrochloride is the long duration of action. Onset and duration of the local anaesthetic efficacy are dependant upon the administration site and dose, but are not influenced by the presence of a vasoconstrictor (e.g., epinephrine). For details concerning the onset and duration of action of Ropivacaine Kabi (see section 4.2).

Healthy volunteers exposed to intravenous infusions tolerated ropivacaine hydrochloride well at low doses and with expected CNS symptoms at the maximum tolerated dose. The clinical experience with ropivacaine hydrochloride indicates a good margin of safety when adequately used in recommended doses.

5.2 **Pharmacokinetic properties**

Absorption and distribution

Ropivacaine hydrochloride has a chiral center and is available as the pure S-(-)-enantiomer. It is highly lipid-soluble. All metabolites have a local anaesthetic effect but of considerably lower potency and shorter duration than that of ropivacaine hydrochloride.
The plasma concentration of ropivacaine hydrochloride depends upon the dose, the route of administration and the vascularity of the injection site. Ropivacaine hydrochloride follows linear pharmacokinetics and the $C_{\text{max}}$ is proportional to the dose.

Ropivacaine hydrochloride shows complete and biphasic absorption from the epidural space with half-lives of the two phases of the order of 14 min and 4 h in adults. The slow absorption is the rate-limiting factor in the elimination of ropivacaine hydrochloride, which explains why the apparent elimination half-life is longer after epidural than after intravenous administration. Ropivacaine hydrochloride shows a biphasic absorption from the caudal epidural space also in paediatric patients.

Ropivacaine hydrochloride has a mean total plasma clearance in the order of 440 ml/min, a renal clearance of 1 ml/min, a volume of distribution at steady state of 47 litres and a terminal half-life of 1.8 h after intravenous administration. Ropivacaine hydrochloride has an intermediate hepatic extraction ratio of about 0.4. It is mainly bound to $\alpha$1-acid glycoprotein in plasma with an unbound fraction of about 6%.

An increase in total plasma concentrations during continuous epidural infusion has been observed, related to a postoperative increase of $\alpha$1-acid glycoprotein.

Variations in unbound, i.e., pharmacologically active, concentration have been much less than in total plasma concentration.

Since ropivacaine hydrochloride has an intermediate to low hepatic extraction ratio, its rate of elimination should depend on the unbound plasma concentration. A postoperative increase in AAG will decrease the unbound fraction due to increased protein binding, which will decrease the total clearance and result in an increase in total plasma concentrations, as seen in the paediatric and adult studies. The unbound clearance of ropivacaine hydrochloride remains unchanged as illustrated by the stable unbound concentrations during postoperative infusion. It is the unbound plasma concentration that is related to systemic pharmacodynamic effects and toxicity.

Ropivacaine hydrochloride readily crosses the placenta and equilibrium in regard to unbound concentration will be rapidly reached. The degree of plasma protein binding in the foetus is less than in the mother, which results in lower total plasma concentrations in the foetus than in the mother.

**Biotransformation and elimination**

Ropivacaine hydrochloride is extensively metabolised, predominantly by aromatic hydroxylation. In total 86% of the dose is excreted in the urine after intravenous administration of which only about 1% relates to unchanged ropivacaine hydrochloride. The major metabolite is 3-hydroxy-ropivacaine, about 37% of which is excreted in the urine, mainly conjugated. Urinary excretion of 4-hydroxy-ropivacaine, the N-dealkylated metabolite (PPX) and the 4-hydroxy-dealkylated metabolite accounts for 1-3%.

Conjugated and unconjugated 3-hydroxy-ropivacaine shows only barely detectable concentrations in plasma.

Regarding metabolites a similar pattern has been found in paediatric patients above one year compared to adults.

There is no evidence of in vivo racemisation of ropivacaine hydrochloride.

**Paediatric patients**

The pharmacokinetics of ropivacaine hydrochloride was characterised in a pooled population PK analysis on data in 192 paediatric patients between 0 and 12 years. Unbound ropivacaine hydrochloride and PPX clearance and ropivacaine hydrochloride unbound volume of distribution.
depend on both body weight and age up to the maturity of liver function, after which they depend largely on body weight. The maturation of unbound ropivacaine hydrochloride clearance appears to be complete by the age of 3 years, that of PPX by the age of 1 year and unbound ropivacaine hydrochloride volume of distribution by the age of 2 years. The PPX unbound volume of distribution only depends on body weight. As PPX has a longer half-life and a lower clearance, it may accumulate during epidural infusion.

Unbound ropivacaine hydrochloride clearance (Clu) for ages above 6 months has reached values within the range of those in adults. Total ropivacaine hydrochloride clearance (Cl) values displayed in the table below are those not affected by the postoperative increase in AAG.

### Estimates of pharmacokinetic parameters derived from the pooled paediatric population PK analysis

<table>
<thead>
<tr>
<th>Age</th>
<th>BW&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Clu&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Vu&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Cl&lt;sup&gt;d&lt;/sup&gt;</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt;&lt;sup&gt;e&lt;/sup&gt;</th>
<th>t&lt;sub&gt;1/2ppx&lt;/sub&gt;&lt;sup&gt;f&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn infant</td>
<td>3.27</td>
<td>2.40</td>
<td>21.86</td>
<td>0.096</td>
<td>6.3</td>
<td>43.3</td>
</tr>
<tr>
<td>1 m</td>
<td>4.29</td>
<td>3.60</td>
<td>25.94</td>
<td>0.143</td>
<td>5.0</td>
<td>25.7</td>
</tr>
<tr>
<td>6 m</td>
<td>7.85</td>
<td>8.03</td>
<td>41.71</td>
<td>0.320</td>
<td>3.6</td>
<td>14.5</td>
</tr>
<tr>
<td>1 y</td>
<td>10.15</td>
<td>11.32</td>
<td>52.60</td>
<td>0.451</td>
<td>3.2</td>
<td>13.6</td>
</tr>
<tr>
<td>4 y</td>
<td>16.69</td>
<td>15.91</td>
<td>55.24</td>
<td>0.633</td>
<td>2.8</td>
<td>15.1</td>
</tr>
<tr>
<td>10 y</td>
<td>32.19</td>
<td>13.94</td>
<td>55.57</td>
<td>0.555</td>
<td>3.3</td>
<td>17.8</td>
</tr>
</tbody>
</table>

<sup>a</sup>Median bodyweight for respective age from WHO database.
<sup>b</sup>Unbound ropivacaine hydrochloride clearance
<sup>c</sup>Ropivacaine hydrochloride unbound volume of distribution
<sup>d</sup>Total ropivacaine hydrochloride clearance
<sup>e</sup>Ropivacaine hydrochloride terminal half life
<sup>f</sup>PPX terminal half life

The simulated mean unbound maximal plasma concentration (Cu<sub>max</sub>) after a single caudal block tended to be higher in newborn infants and the time to Cu<sub>max</sub> (t<sub>max</sub>) decreased with an increase in age. Simulated mean unbound plasma concentrations at the end of a 72 h continuous epidural infusion at recommended dose rates also showed higher levels in newborn infants as compared to those in infants and children (see section 4.4).

### Simulated mean and observed range of unbound Cu<sub>max</sub> after a single caudal block

<table>
<thead>
<tr>
<th>Age group</th>
<th>Dose</th>
<th>Cu&lt;sub&gt;max&lt;/sub&gt;&lt;sup&gt;a&lt;/sup&gt;</th>
<th>t&lt;sub&gt;max&lt;/sub&gt;&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Cu&lt;sub&gt;max&lt;/sub&gt;&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1 m</td>
<td>2.00</td>
<td>0.0582</td>
<td>2.00</td>
<td>0.05-0.08 (n=5)</td>
</tr>
<tr>
<td>1-6 m</td>
<td>2.00</td>
<td>0.0375</td>
<td>1.50</td>
<td>0.02-0.09 (n=18)</td>
</tr>
<tr>
<td>6-12 m</td>
<td>2.00</td>
<td>0.0283</td>
<td>1.00</td>
<td>0.01-0.05 (n=9)</td>
</tr>
<tr>
<td>1-10 y</td>
<td>2.00</td>
<td>0.0221</td>
<td>0.50</td>
<td>0.01-0.05 (n=60)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Unbound maximal plasma concentration
<sup>b</sup>Time to unbound maximal plasma concentration
<sup>c</sup>Observed and dose-normalised unbound maximal plasma concentration

At 6 months, the breakpoint for change in the recommended dose rate for continuous epidural infusion, unbound ropivacaine hydrochloride clearance has reached 34% and unbound PPX 71% of its mature value. The systemic exposure is higher in newborn infants and also somewhat higher in infants between 1 and 6 months compared to older infants and children, which is related to the immaturity of
their liver function. However, this is partly compensated for by the recommended 50% lower dose rate for continuous infusion in infants below 6 months.

Simulations on the sum of unbound plasma concentrations of ropivacaine hydrochloride and PPX, based on the PK parameters and their variance in the population analysis, indicate that for a single caudal block the recommended dose must be increased by a factor of 2.7 in the youngest group and a factor of 7.4 in the 1–10 year group in order for the upper prediction 90% confidence interval limit to touch the threshold for systemic toxicity. Corresponding factors for the continuous epidural infusion are 1.8 and 3.8, respectively.

5.3 Preclinical safety data

Based on conventional studies of safety pharmacology, single and repeated dose toxicity, reproduction toxicity, mutagenic potential and local toxicity, no hazards for humans were identified other than those which can be expected on the basis of the pharmacodynamic action of high doses of ropivacaine hydrochloride (e.g., CNS signs, including convulsions, and cardiotoxicity).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Sodium chloride
- Hydrochloric acid (for pH adjustment)
- Sodium hydroxide (for pH adjustment)
- Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

In alkaline solutions precipitation may occur as ropivacaine hydrochloride shows poor solubility at pH > 6.0.

6.3 Shelf life

Shelf-life before opening
3 years

Shelf-life after opening
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C.

6.4 Special precautions for storage

Do not refrigerate or freeze.

For storage conditions after first opening the medicinal product, see section 6.3.

6.5 Nature and contents of container
10 ml transparent polypropylene ampoule.

The polypropylene ampoules are specially designed to fit Luer lock and Luer fit syringes.

Pack sizes:
1, 5, 10 ampoule(s) in blister pack

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Handling
Ropivacaine Kabi products are preservative free and is intended for single use only. Discard any unused solution.

The medicinal product should be visually inspected prior to use. The solution should only be used if it is clear, practically free from particles and if the container is undamaged.

The intact container must not be re-autoclaved.

Disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

[To be completed nationally]

{Name and address}
{tel}
{fax}
{e-mail}

8. MARKETING AUTHORISATION NUMBER(S)

[To be completed nationally]

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: {DD month YYYY}
Date of latest renewal: {DD month YYYY}

[To be completed nationally]

10. DATE OF REVISION OF THE TEXT

{MM/YYYY}
[To be completed nationally]